National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Economic Evaluation of Prasugrel (Efient®) for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing primary or delayed percutaneous coronary intervention.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
July 2009 February 2010  Reimbursement Recommended

The review group consider that prasugrel, co-administered with aspirin, is cost-effective in patients with acute coronary syndrome undergoing primary or delayed percutaneous coronary intervention in the Irish healthcare setting.

Prasugrel (Efient) summary